Capital Fund Management (CFM)
RXRX icon

Capital Fund Management (CFM)’s Recursion Pharmaceuticals RXRX Stock Holding History

Capital Fund Management (CFM)’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,909,480
Closed -$5.86M – 2340
2026
Q1 		$5.86M Buy
1,909,480
+130,504
+7% +$504K 0.03% 815
2025
Q4 		$7.28M Buy
1,778,976
+1,052,952
+145% +$5.22M 0.02% 989
2025
Q3 		$3.54M Buy
726,024
+5,498
+0.8% +$28.9K 0.01% 1454
2025
Q2 		$3.65M Buy
720,526
+513,258
+248% +$2.52M 0.01% 1341
2025
Q1 		$1.1M Buy
207,268
+23,472
+13% +$171K ﹤0.01% 1639
2024
Q4 		$1.24M Buy
+183,796
New +$1.24M ﹤0.01% 1690

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Capital Fund Management (CFM)'s RXRX Position: Q2 2026 in Review

Capital Fund Management (CFM) sold out of Recursion Pharmaceuticals (RXRX) in Q2 2026, closing a stake of 1,909,480 shares — an estimated $5.86M sold.

Capital Fund Management (CFM) first reported a position in RXRX in Q4 2024 and held it in 6 quarters. The position peaked at $7.28M in Q4 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Capital Fund Management (CFM) reported no remaining Recursion Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 1,909,480 Recursion Pharmaceuticals shares in Q2 2026, an estimated $5.86M.
  • Capital Fund Management (CFM) first reported a position in Recursion Pharmaceuticals in Q4 2024 and held it in 6 quarters.
  • Capital Fund Management (CFM)'s Recursion Pharmaceuticals position peaked at $7.28M in Q4 2025.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2026, filed 13 Aug 2026.